News

CliCr® and CliCr® derivatives are available via Iris Biotech GmbH

January 26, 2023
Iris Biotech sells CliCr® and CliCr® reagents.
Read more
CliCr® and CliCr® derivatives are available via Iris Biotech GmbH

Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering

January 17, 2023
- Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox...
Read more
Lonza Collaborates with Cristal Therapeutics and  McSAF to Expand Bioconjugates Offering

MIMETAS Elected Most Innovative Company of the Netherlands

November 02, 2022
Mimetas is the winner of the Dutch Innovation Award 2022.
Read more
MIMETAS Elected Most Innovative Company of the Netherlands

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

October 18, 2022
Synaffix B.V. today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® m...
Read more
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Professor Melief to receive 2022 SITC Pedro J. Romero Award

September 08, 2022
Professor Melief to receive 2022 SITC Pedro J. Romero Award
Read more
Professor Melief to receive 2022 SITC Pedro J. Romero Award

MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

September 07, 2022
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

July 15, 2022
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

FDA Accepts Byondis' BLA for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

July 12, 2022
Byondis acquired the technology for the development of its anti-HER2 ADC drug from Aglaia's portfolio company Syntarga in 2010.
Read more

In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed

June 16, 2022
Scientists from MIMETAS introduce a platform for routine grafting of liver and other tissues on an in vitro grown microvascular...
Read more
In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed

Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

May 27, 2022
ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficac...
Read more
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

Home > News

© 2023 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds